PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PDL BioPharma Announces 2016 First Quarter Dividend
PDL BioPharma Announces Closing of Transaction Related to LENSAR Debt Investment
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Discloses Recent Notable Payments From Income Generating Assets